Nanostructured boron agents for boron neutron capture therapy: a review of recent patents.

Med Rev (2021)

Sunshine Lake Pharma Co. Ltd, Dongguan, Guangdong Province, China.

Published: October 2023

AI Article Synopsis

  • Boron neutron capture therapy (BNCT) is an emerging cancer treatment that relies on specific boron delivery agents to target tumors effectively.
  • Current boron compounds like sodium mercaptoundecahydro-dodecaborate (BSH) and boronophenylalanine (BPA) are used in clinical settings but have limitations in tumor selectivity.
  • The article discusses advances in boron nanomaterials as improved delivery systems for BNCT and aims to encourage further exploration of these nanomaterials by summarizing recent patents.

Article Abstract

Boron neutron capture therapy (BNCT) is a potential radiation therapy modality for cancer, and tumor-targeted stable boron-10 (B) delivery agents are an important component of BNCT. Currently, two low-molecular-weight boron-containing compounds, sodium mercaptoundecahydro--dodecaborate (BSH) and boronophenylalanine (BPA), are mainly used in BNCT. Although both have suboptimal tumor selectivity, they have shown some therapeutic benefit in patients with high-grade glioma and several other tumors. To improve the efficacy of BNCT, great efforts have been devoted for the development of new boron delivery agents with better uptake and favorable pharmacokinetic profiles. This article reviews the application and research progress of boron nanomaterials as boron carriers in boron neutron capture therapy and hopes to stimulate people's interest in nanomaterial-based delivery agents by summarizing various kinds of boron nanomaterial patents disclosed in the past decade.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10811353PMC
http://dx.doi.org/10.1515/mr-2023-0013DOI Listing

Publication Analysis

Top Keywords

boron neutron
12
neutron capture
12
capture therapy
12
delivery agents
12
boron
7
nanostructured boron
4
agents
4
boron agents
4
agents boron
4
therapy
4

Similar Publications

Objective: Boron Neutron Capture Therapy (BNCT) is a novel precision radiotherapy. The key to BNCT application lies in the effective targeting and retention of the boron-10 (B) carrier. Among the various compounds studied in clinical settings, 4-boronophenylalanine (BPA) become the most prevalent one currently.

View Article and Find Full Text PDF

Background: Boron neutron capture therapy (BNCT) is an innovative binary form of radiation therapy with high selectivity towards cancer tissue based on the neutron capture reaction B(n,α)Li, consisting in the exposition of patients to neutron beams after administration of a boron compound with preferential accumulation in cancer cells. The high linear energy transfer products of the ensuing reaction deposit their energy at the cell level, sparing normal tissue. Although progress in accelerator-based BNCT has led to renewed interest in this cancer treatment modality, in vivo dose monitoring during treatment still remains not feasible and several approaches are under investigation.

View Article and Find Full Text PDF

In this work, a series of boronated amidines based on the -dodecaborate anion and amino acids containing an amino group in the side chain of the general formula [BHNHC(NH(CH)CH(NH)COOH)CH], where n = 2, 3, 4, were synthesized. These derivatives contain conserved α-amino and α-carboxyl groups recognized by the binding centers of the large neutral amino acid transporter (LAT) system, which serves as a target for the clinically applied BNCT agent para-boronophenylalanine (BPA). The paper describes several approaches to synthesizing the target compounds, their acute toxicity studies, and tumor uptake studies in vivo in two tumor models.

View Article and Find Full Text PDF

We aimed to explore the possibility of realizing a beam shaping assembly (BSA) driven by a 15-kW beam of 33-MeV electrons of an electron linear accelerator (LINAC) when a boronophenylalanine is adopted as a boron carrier. Simulation calculations were performed to design two types of BSAs driven by the small LINAC. The one was an experimental BSA, and the other was a high-performance BSA.

View Article and Find Full Text PDF

Boron (B) neutron capture therapy (BNCT) is a novel non-invasive targeted cancer therapy based on the nuclear capture reaction B (n, alpha) Li that enables the death of cancer cells without damaging neighboring normal cells. However, the development of clinically approved boron drugs remains challenging. We have previously reported on self-forming nanoparticles for drug delivery consisting of a biodegradable polymer, namely, "AB-type" Lactosome nanoparticles (AB-Lac particles)- highly loaded with hydrophobic B compounds, namely -Carborane (Carb) or 1,2-dihexyl--Carborane (diC6-Carb), and the latter (diC6-Carb) especially showed the "molecular glue" effect.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!